Sign Out
Pharmacology: Pharmacodynamics: Mechanism of Action: The vaccine is a live attenuated virus. Following administration, the virus replicates locally and elicits neutralising antibodies and cell-mediated immune responses that are specific to the Japanese encephalitis virus. Available results indicate that protection is mainly mediated by neutralising antibodies.
In nonclinical studies, all animals that received a single dose of the vaccine developed specific neutralising antibodies against Japanese encephalitis virus and were protected against infection by a virulent Japanese encephalitis virus experimental challenge.
A single dose administration of IMOJEV is as immunogenic as a three-dose regimen of an inactivated Japanese encephalitis comparator vaccine administered in adults 18 years of age and over. A seroprotective level of antibodies is generally reached 14 days after vaccination.
In persons 9 months of age and over, a seroprotective level of antibodies is generally reached 28 days after vaccination.
Pharmacokinetics: Not applicable.
Continue with Google